| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman | 08:30 – 08:35 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Fabien Zoulim View Bio Prof. Jinlin Hou |
|
| HBV Cure: HBV Cure States from the Asian Consensus Conference – Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
|
| Challenges to achieve functional cure Adj. Prof. Veronica Miller, UC Berkeley, Public Health, USA View Bio |
08:50 – 09:10 |
| Landscape of functional cure 2026 after Bepirovirsen phase 3 results – Prof. Fabien Zoulim, Universite Claude Bernard Lyon 1, France View Bio |
09:10 – 09:30 |
| Q&A | 09:30 – 09:45 |
| Tea Break | 09:45 – 10:15 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Fabien Zoulim View Bio Prof. Jinlin Hou |
|
| Free paper: Clinically meaningful functional cure rates in virologically suppressed Chinese patients with chronic hepatitis B virus infection treated with bepirovirsen: A subanalysis of the B-Well Phase 3 trials, Prof. Jin Lin Hou, Nanfang University, Guangzhou, China |
10:15 – 10:30 |
| Free paper: Projected impact of hepatitis B virus functional cure therapies on liver disease burden in China: A modelling analysis, Dr. Devin Razavi-Shearer |
10:30 – 10:45 |
| Free paper: Metabolic Dysfunction and Its Impact on Chronic Hepatitis B Progression Hepatitis B Functional Cure: Real-World Clinical Perspectives, Dr. Preeti, Agarwal |
10:45 – 11:00 |
| Q&A | 11:00 – 11:15 |
| Virological Insights into functional cure Moderators: Prof. Thomas Tu View Bio |
|
| Virological Cure and complete cure: achievable or imaginary? – Prof. Massimo Levrero, Universite Claude Bernard Lyon 1, France View Bio |
11:15 – 11:35 |
| Integrated HBV: what’s important? Burden, integration site or clonal expansion – Prof. Thomas Tu, Westmead Institute for Medical Research, Australia View Bio |
11:35 – 11:55 |
| Free paper : Intrahepatic viral integration more than reservoir size dictates the HBsAg loss trajectory in Chronic Hepatitis B, Dr. Cameron Soulette Gilead Science Inc |
11:55 – 12:10 |
| Q&A | 12:10 – 12:20 |
| Lunch | 12:20 – 13:20 |
| Intrahepatic microenvironment Moderator: Prof. Massimo Levrero View Bio |
|
| Spatial transcriptomics: state of the Science and Art – Charting the Spatial Whole Transcriptome and Multiomic Frontier for Complete Biology Dr. Prajan Divakar, Bruker Corporation |
13:20 – 13:35 |
| Spatial proteomics: Advancements in cyclic immunofluorescence methods for liver tissue imaging and spatial profiling enabled by the CellScape XR platform. Dr. Benton Berigan, Bruker Corporation |
13:35 – 13:40 |
| Spatial Transcriptomics in HBV – Prof. Jane McKeating, Oxford |
13:40 – 14:00 |
| Intrahepatic immune correlates of functional cure – Prof. Adam Gehring, University of Toronto, Canada View Bio |
14:00 – 14:20 |
| Free paper: Spatial Transcriptomics of CHB and HBsAg loss using CosMx, Dr. Aravind Sivakumar et al |
14:20 – 14:35 |
| Q&A | 14:35 – 14:50 |
| Animal Models Moderator: Prof. Qingfeng Chen View Bio |
|
| Benefits and limitations of animal models to assess antivirals and immune modulators for Functional Cure. Prof. Maura Dandri, University Medical Center Hamburg-Eppendorf Germany View Bio |
14:50 – 15:10 |
| Free paper: Impact of Bulevirtide on Hepatocyte Transcriptional Programs in a Humanized Mouse Model of HDV Infection. Dr. Wakae Kousho (abstract 48) |
15:10 – 15:30 |
| Q&A | 15:30 – 15:45 |
| Tea Break | 15:45 – 16:00 |
| Strategies with existing agents Moderator: Prof. Man Fung Yuen View Bio |
|
| Stopping nucleoside analogues: is there still a role in FC? – Prof. Norah Terrault, Keck School of Medicine, University of Southern California. View Bio |
16:00 – 16:20 |
| Peginterferon: never say die – Prof. Teerha Piratsuvith, Prince of Songkla University, Thailand View Bio |
16:20 – 16:40 |
| Free paper To Stop or Not to Stop? End-of-Treatment HBcrAg for Predicting Relapse After Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B: A Diagnostic Test Accuracy Meta-Analysis. Budiman et al (abstract 35) | 16:40 – 17:00 |
| Q&A | 17:00 – 17:15 |
| End of day 1 | 17:15 |
The Science of HBV Cure Meeting 2026
September, 2026
4
September, 2026
5
| Programme | Time (SGT) |
|---|---|
| Biomarkers Moderators: Prof. Teerha Piratvisuth View Bio |
|
| HBsAg levels in real world and for clinical trials of novel therapies – Prof. Man-Fung Yuen, Hong Kong View Bio |
08:30 – 08:50 |
| Biomarkers that corelate with cccDNA – Prof. Jordan Feld, University of Toronto, Canada View Bio |
08:50 – 09:10 |
| Using Biomarkers for management of CHB with novel therapies – Prof. Yasuhito Tanaka, Kumamoto University View Bio |
09:10 – 09:30 |
| Q&A | 09:30 – 09:40 |
| RNA interference Moderators: Prof. Mala Maini View Bio |
|
| Anti-sense oligonucleotides: are they immune modulators? – Prof. Antonio Bertoletti, Duke NUS Graduate School of Medicine, Singapore View Bio |
09:40 – 10:00 |
| The role of siRNA in HBV cure therapies – Prof. MF Yuen, Hong Kong University, Hong Kong View Bio |
10:00 – 10:20 |
| Q&A | 10:20– 10:30 |
| Tea Break | 10:30 – 10:45 |
| Poster Presentation Moderated by Dr. Lee Yin Mei (NUHS) |
10:45 – 11:15 |
| Delta Cure Moderator: Prof. Pietro Lampertico View Bio |
|
| Delta Cure update – Prof. Heiner Wedemeyer, Hannover Medical School, Germany View Bio |
11:15 – 11:35 |
| Novel therapeutics for Delta Cure Prof. Pietro Lampertico, Italy View Bio |
11:35 – 11:55 |
| Q&A | 11:55 – 12:05 |
| Lunch | 12:05 – 13:10 |
| Invited Pharma Presentations Moderators: Prof. Lim Seng Gee View Bio and Prof. Adam Gehring View Bio |
|
| Bepirovirsen: The Journey So Far Attila Mihalyi (Vice President, Global Medical Lead, Hepatitis B) GSK |
13:10 – 13:25 |
| AHB-137, update Dr. Guo Feng Cheng, CEO, Ausperbio Therapeutics Inc |
13:25 – 13:40 |
| siRNA+Neutralizing antibody – Dr. Wu Kai, CEO, Hepa Thera Biopharmaceutical Co., Ltd |
13:40 – 13:55 |
| VRON-0200: Priming Immunity for CHB Cure: A Clinical Update Dr. Sue Currie, COO, Virion Therapeutics LLC |
13:55 – 14:10 |
| Q&A | 14:10 – 14:20 |
| Immunology Moderator: Prof. Antonio Bertoletti View Bio |
|
| The challenges and promise of immune modulation for Functional Cure – Prof. Mala Maini, University College London, UK View Bio |
14:20 – 14:40 |
| Antibody therapeutics in the quest for Functional Cure – Prof. Adam Gehring, University of Toronto, Canada View Bio |
14:40 – 15:00 |
| Free paper: Characterisation and discovery of epitopes of anti-HBe during HBeAg seroconversion, Dr. Low Heng Boon, National University of Singapore |
15:00 – 15:15 |
| Free paper: Peg-interferon modulates the trajectory of peripheral immunity in functionally cured chronic hepatitis B patients, Dr. Neo Shi Yong (Singapore Immunology Network, A*Star) et al (abstract 26) |
15:15 – 15:30 |
| Free paper: First-in-Human Safety of the Dendritic Cell–Targeting Immunotherapy SN2001 with Translational Evidence Supporting Restoration of HBV-Specific Cellular Immunity, Yuenian Eric Shi et al (CEO, Chimegen bio) (abstract 50) |
15:30 – 15:45 |
| Q&A | 15:45 – 16:00 |
| Tea Break | 16:00 – 16:15 |
| Gene Therapy Moderators: Prof. Fabien Zoulim View Bio |
|
| Early clinical results of gene/epigenetic editing – Prof. Ed Gane, University of Auckland, New Zealand View Bio |
16:15 – 16:35 |
| The safety of gene editing: What to measure and for how long? – Dr. Wei Leong Chew GIS, ASTAR View Bio |
16:35 – 16:55 |
| Q&A | 16:55 – 17:10 |
| Closing remarks from Chairman | 17:10 – 17.15 |